HAVCR2 and neoplasm: Studies have shown that Gal-9 enhances anti-tumor immunity in mice with tumors by promoting the maturation of CD11c+ DCs, which in turn activate CD4+ TIM-3+ and CD8+ TIM-3+ T cells.